企業プロフィール
Aprea Therapeutics 株価・ニュース・カタリスト
- ティッカー:
- APRE
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
0.69 USD (+1.49%)
終値
最終更新: 2026年8月17日
9.46M USD
時価総額
株価変動の要因
As of Aug 17, 2026, APRE closed up 1.49% at $0.6900. No new same-company headline was identified in the current news window.
企業概要
DNA Damage Response Oncology
Aprea Therapeutics develops precision medicines that exploit vulnerabilities in cancer-cell DNA replication and repair. Its programs target biomarker-defined tumors while seeking to limit effects on healthy cells.
APR-1051
APR-1051 is a selective oral WEE1 inhibitor in the Phase 1 ACESOT-1051 study for advanced solid tumors. The program is designed to improve the therapeutic window relative to earlier WEE1 inhibitors.
Biomarker-Directed Expansion
Aprea is expanding APR-1051 in uterine serous carcinoma and cyclin E-overexpressing platinum-resistant ovarian cancer. It also plans combination work in HPV-positive head-and-neck cancer and colorectal cancer.
ATRN-119
ATRN-119 is a macrocyclic ATR inhibitor that has completed Phase 1 dose escalation. Aprea is evaluating potential combination development with immunotherapy, chemotherapy, antibody-drug conjugates, and radiation.
今後のカタリスト
- Clinical data update from the Phase 1 ACESOT-1051 study of APR-1051 at a medical meeting in the fourth quarter of 2026.
- Potential entry of Aprea's macrocyclic DYRK1A/B inhibitor into IND-enabling studies in the fourth quarter of 2026.
- Completion of APR-1051 dose escalation and backfill expansion in the second quarter of 2027.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。